170 related articles for article (PubMed ID: 19601803)
1. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
Zhou SF; Liu JP; Lai XS
Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
[TBL] [Abstract][Full Text] [Related]
2. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
3. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX; Chen XW; Zhou ZW; Zhou SF
Drug Metab Rev; 2015; 47(4):470-519. PubMed ID: 26574146
[TBL] [Abstract][Full Text] [Related]
4. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.
Wang B; Zhou SF
Curr Med Chem; 2009; 16(31):4066-218. PubMed ID: 19754423
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.
Mann A; Tyndale RF
Eur J Neurosci; 2010 Apr; 31(7):1185-93. PubMed ID: 20345925
[TBL] [Abstract][Full Text] [Related]
6. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
7. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
8. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
9. Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6.
Kalgutkar AS; Zhou S; Fahmi OA; Taylor TJ
Drug Metab Dispos; 2003 May; 31(5):596-605. PubMed ID: 12695348
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
12. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap).
Mo SL; Liu WF; Chen Y; Luo HB; Sun LB; Chen XW; Zhou ZW; Sneed KB; Li CG; Du YM; Liang J; Zhou SF
Comb Chem High Throughput Screen; 2012 Jan; 15(1):36-80. PubMed ID: 21846324
[TBL] [Abstract][Full Text] [Related]
13. Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528.
Kotsuma M; Hanzawa H; Iwata Y; Takahashi K; Tokui T
Drug Metab Dispos; 2008 Sep; 36(9):1938-43. PubMed ID: 18524873
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.
Livezey M; Nagy LD; Diffenderfer LE; Arthur EJ; Hsi DJ; Holton JM; Furge LL
Drug Metab Lett; 2012 Mar; 6(1):7-14. PubMed ID: 22372551
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
[TBL] [Abstract][Full Text] [Related]
16. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates.
Le Bourdonnec B; Leister LK
Curr Med Chem; 2009; 16(24):3093-121. PubMed ID: 19689286
[TBL] [Abstract][Full Text] [Related]
18. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.
Yu AM; Idle JR; Gonzalez FJ
Drug Metab Rev; 2004 May; 36(2):243-77. PubMed ID: 15237854
[TBL] [Abstract][Full Text] [Related]
19. Understanding CYP2D6 interactions.
de Groot MJ; Wakenhut F; Whitlock G; Hyland R
Drug Discov Today; 2009 Oct; 14(19-20):964-72. PubMed ID: 19638317
[TBL] [Abstract][Full Text] [Related]
20. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]